PAH patients may ditch frequent inhalers for a Once-Daily pill

NCT ID NCT07356375

Not yet recruiting Symptom relief Sponsor: University of Sao Paulo General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 32 adults with pulmonary arterial hypertension (PAH) whose doctors decide to switch them from inhaled iloprost (taken several times a day) to oral selexipag (a pill). Researchers will use questionnaires to see if the switch improves quality of life, treatment satisfaction, and how well patients stick with their medication. A comparison group staying on iloprost will also be observed. No experimental treatments are involved—all care is routine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Selexipag (oral medication)
What this could lead to: If successful, this study could show that switching to a once-daily pill improves daily life and makes it easier for people with PAH to stick with their treatment.
What could go wrong: This is a small, observational study (32 people) that does not test a new drug—it simply observes a routine switch. Results may not apply to everyone with PAH.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION (PAH) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary arterial hypertension Treatment Adherence and Compliance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PULMONARY ARTERIAL HYPERTENSION (PAH)

More trials for these conditions

Other studies related to the condition(s) this trial covers.